Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
Journal Article (Journal Article)
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.
- Tempero, MA; Arnoletti, JP; Behrman, SW; Ben-Josef, E; Benson, AB; Casper, ES; Cohen, SJ; Czito, B; Ellenhorn, JDI; Hawkins, WG; Herman, J; Hoffman, JP; Ko, A; Komanduri, S; Koong, A; Ma, WW; Malafa, MP; Merchant, NB; Mulvihill, SJ; Muscarella, P; Nakakura, EK; Obando, J; Pitman, MB; Sasson, AR; Tally, A; Thayer, SP; Whiting, S; Wolff, RA; Wolpin, BM; Freedman-Cass, DA; Shead, DA; National Comprehensive Cancer Networks,
- June 1, 2012
Volume / Issue
- 10 / 6
Start / End Page
- 703 - 713
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States